- ￥1521 - 11934
- Biorbyt
- 英国
- orb1819214
- 2026年08月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
源叶现货试剂/标准品，库存足，周末发货Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
详询
- 保质期：
12 months from date of receipt.
- 英文名：
mTOR inhibitor 9f
- 库存：
99
- 供应商：
Biorbyt
- CAS号：
1144075-42-2
- 规格：
1 mg/5 mg/10 mg/25 mg/50 mg/100 mg/200 mg
| 规格： | 1 mg | 产品价格： | ￥1521.0 |
|---|---|---|---|
| 规格： | 5 mg | 产品价格： | ￥2925.0 |
| 规格： | 10 mg | 产品价格： | ￥3744.0 |
| 规格： | 25 mg | 产品价格： | ￥5382.0 |
| 规格： | 50 mg | 产品价格： | ￥7020.0 |
| 规格： | 100 mg | 产品价格： | ￥9126.0 |
| 规格： | 200 mg | 产品价格： | ￥11934.0 |
描述: The compound 9f is a potent and selective mTOR inhibitor, exhibiting IC50 values of 1.25 nM for mTOR and 82 nM for PI3Kα. It serves as a valuable chemical probe for studying mTOR signaling in cancer research and has demonstrated utility in both cellular and in vivo models of tumor growth.
别名: 1(4(4(8oxa3azabicyclo[3.2.1]octan3yl)thieno[3,2d]pyrimidin2yl)phenyl)3phenylurea, mTOR inhibitor 9f, mTOR, PI3Kα
靶点: PI3K,mTOR
分子式: C25H23N5O2S
分子量: 457.55
纯度: 98.39% (May vary between batches)
SMILES: N(C(NC1=CC=CC=C1)=O)C2=CC=C(C3=NC(=C4C(=N3)C=CS4)N5CC6OC(C5)CC6)C=C2
溶解度: DMSO:45 mg/mL (98.35 mM)
研究领域: Pharmacology & Drug Discovery; Cell Biology, Signal Transduction
保存条件: -20°C
备注: For research use only.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The mammalian target of rapamycin (mTOR) is the catalytic subunit of two multiprotein complexes, mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2). Clinically used rapamycin and rapalogs are FKBP12-dependent allosteric inhibitors of mTORC
Expanding Human T Regulatory Cells with the mTOR-Inhibitor Rapamycin
CD4+ CD25+ FOXP3+ T regulatory (Treg) cells are pivotal for the induction and maintenance of peripheral tolerance in both mice and humans. The possibility to use Treg cells for the treatment of T-cell-mediated diseases has recently gained
Development of ATP-Competitive mTOR Inhibitors
mTOR inhibitor rapamycin and structurally related rapalogs have failed to show significant single-agent antitumor efficacy in most types of cancer. This limited clinical success may be due to the inability of the rapalogs to maintain a complete blockade
技术资料暂无技术资料 索取技术资料
